Bora Pharmaceuticals become the First Pharmaceuticals in Taiwan to trade on OTCQX

On January 8, 2026, OTC Markets Group Inc. (OTCQX: OTCM) announced that Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) has qualified to trade on the OTCQX Best Market. Bora began trading on January 8 under the symbol “BORAY,” according to the company’s release distributed via ADR Web. OTC Markets said U.S. investors can access Bora’s current financial disclosure and real-time Level 2 quotes through its website.

“BORAY” Launches on OTCQX

OTC Markets Group, which describes itself as an operator of regulated markets for trading 12,000 U.S. and international securities, said it welcomed Bora Pharmaceuticals to OTCQX. In the announcement, Bora is described as an international contract development and manufacturing organization and specialty pharmaceutical company.

The company said Bora’s U.S. trading begins today on OTCQX under “BORAY.” OTC Markets added that investors can find disclosure materials and real-time Level 2 quotes on its platform.

OTCQX Framework and Reporting Pathway

OTC Markets said OTCQX provides companies an efficient, cost-effective route to access U.S. capital markets. For issuers listed on a qualified international exchange, the group said streamlined market standards allow companies to use home market reporting to make information available in the United States.

To qualify for OTCQX, OTC Markets said companies must meet financial standards, follow best-practice corporate governance, and demonstrate compliance with applicable securities laws.

Executives Frame the Milestone and ADR Program

Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group, said Bora is the first Taiwanese issuer to join the OTCQX Market, adding that the step increases Bora’s visibility among U.S. investors and reflects OTCQX’s reach across issuers from 38 countries.

Bobby Sheng, Chairman of Bora Group, said the U.S. trading launch is being conducted through a U.S. Level 1 ADR program while Bora maintains its primary listing in Taiwan. He said the move expands access for U.S. investors, aims to enhance shareholder liquidity, and aligns with Bora’s long-term strategic direction. 

Sheng also said Bora operates across Taiwan, the United States, and Canada, with more than 95% of revenue generated outside Taiwan across more than 100 markets. He cited a strong balance sheet, disciplined capital allocation, and a consistent dividend policy, and said the expanded U.S. capital markets access, alongside a commitment to transparency, supports long-term value creation.

Reporting reference based on the statement in:
https://bora-corp.com/otcqx_boray/

Author

Oscar Wu

Fostering knowledge sharing to create a more fluid and transparent information landscape.

Related Post

JPM 2026

Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps

2026-02-03

JPM 2026

From Capacity Upgrades to Tech Licensing: Global Strategies of Samsung Biologics, Celltrion, and Alteogen

2026-01-21

Prime

JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb

2026-01-15